Bristol-Myers set to get a boost in China as Opdivo aces PhIII lung cancer study early
Bristol-Myers Squibb appears poised to win a big niche in China’s cancer drug market. The company reported Thursday night that their Phase III comparing their checkpoint inhibitor Opdivo against docetaxel — run primarily in China — proved their therapy was more effective in treating second-line non-small cell lung cancer patients.
Bristol-Myers $BMY is holding on to the actual data on overall survival from Checkmate-078, but China’s FDA has the marketing application under review. Investigators recruited 451 of 504 patients in China.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.